ATE261307T1 - Verwendung von misoprostol und/oder misoprostolsäure zur behandlung von erektionsstörungen - Google Patents

Verwendung von misoprostol und/oder misoprostolsäure zur behandlung von erektionsstörungen

Info

Publication number
ATE261307T1
ATE261307T1 AT98913967T AT98913967T ATE261307T1 AT E261307 T1 ATE261307 T1 AT E261307T1 AT 98913967 T AT98913967 T AT 98913967T AT 98913967 T AT98913967 T AT 98913967T AT E261307 T1 ATE261307 T1 AT E261307T1
Authority
AT
Austria
Prior art keywords
misoprostol
erective
disorder
treat
misoprostolic
Prior art date
Application number
AT98913967T
Other languages
English (en)
Inventor
Panagiotis Kanakaris
Petros Karouzakis
Original Assignee
Panagiotis Kanakaris
Petros Karouzakis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Panagiotis Kanakaris, Petros Karouzakis filed Critical Panagiotis Kanakaris
Application granted granted Critical
Publication of ATE261307T1 publication Critical patent/ATE261307T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Urology & Nephrology (AREA)
  • Inorganic Chemistry (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT98913967T 1997-05-06 1998-04-22 Verwendung von misoprostol und/oder misoprostolsäure zur behandlung von erektionsstörungen ATE261307T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GR97100172 1997-05-06
PCT/GR1998/000012 WO1998050039A1 (en) 1997-05-06 1998-04-22 Use of misoprostol or/and misoprostol acid for preparing drug in order to cure erectile dysfunction

Publications (1)

Publication Number Publication Date
ATE261307T1 true ATE261307T1 (de) 2004-03-15

Family

ID=10942965

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98913967T ATE261307T1 (de) 1997-05-06 1998-04-22 Verwendung von misoprostol und/oder misoprostolsäure zur behandlung von erektionsstörungen

Country Status (10)

Country Link
US (2) US6210343B1 (de)
EP (1) EP0980245B1 (de)
JP (1) JP2001525803A (de)
AT (1) ATE261307T1 (de)
AU (1) AU6848098A (de)
DE (2) DE69822295T2 (de)
ES (1) ES2216279T3 (de)
GR (1) GR1002847B (de)
PT (1) PT980245E (de)
WO (1) WO1998050039A1 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GR1002847B (el) 1997-05-06 1998-01-27 Χρηση της μισοπροστολης ή/και της μισοπροστολης οξυ για την παρασκευη φαρμακευτικου προιοντος για τη θεραπευτικη αντιμετωπιση των δυσλειτουργιων της στυσεως
US7087240B1 (en) * 1998-06-25 2006-08-08 Lavipharm Laboratories Inc. Device and method for the treatment of erectile dysfunction
GR1003199B (el) 1998-08-14 1999-09-01 Χρηση της μισοπροστολης ή και της μισοπροστολης οξυ για την παρασκευη φαρμακευτικου προιοντος για τη θεραπευτικη αντιμετωπιση της σεξουαλικης δυσλειτουργιας στις γυναικες
US6825234B2 (en) 1998-12-10 2004-11-30 Nexmed (Holdings) , Inc. Compositions and methods for amelioration of human female sexual dysfunction
US7176238B1 (en) 1999-03-01 2007-02-13 Nitromed Inc. Nitrostated and nitrosylated prostaglandins, compositions and methods of use
AU2003208309A1 (en) * 2002-02-22 2003-09-09 Hans Gregersen Method and apparatus for investigating force-deformation properties in muscles in walls of bodily hollow systems
US7037257B1 (en) 2002-08-22 2006-05-02 Koenig J Frank Erectile dysfuction treatments comprising momentary vacuum therapy alone or with medications
US8287474B1 (en) 2002-08-22 2012-10-16 Koenig J Frank Method and apparatus for noninvasively increasing whole body blood flow and noninvasive physical exercise of limbs from the outside and from within the limb to treat diseases throughout the body
GB0222522D0 (en) 2002-09-27 2002-11-06 Controlled Therapeutics Sct Water-swellable polymers
US20050255161A1 (en) * 2004-05-10 2005-11-17 Servet Buyuktimkin Method for the long term stabilization of labile compounds at room temperature in pharmaceutical preparations containing water
GB0417401D0 (en) * 2004-08-05 2004-09-08 Controlled Therapeutics Sct Stabilised prostaglandin composition
WO2006133048A2 (en) * 2005-06-03 2006-12-14 Duramed Pharmaceuticals, Inc. Pharmaceutical compositions comprising prostanoid-receptor agonists and methods of making and using the same
GB0613333D0 (en) 2006-07-05 2006-08-16 Controlled Therapeutics Sct Hydrophilic polyurethane compositions
GB0613638D0 (en) 2006-07-08 2006-08-16 Controlled Therapeutics Sct Polyurethane elastomers
GB0620685D0 (en) 2006-10-18 2006-11-29 Controlled Therapeutics Sct Bioresorbable polymers
JP2010095454A (ja) * 2008-10-14 2010-04-30 Cyclochem:Kk 抗菌組成物
WO2010070617A1 (en) * 2008-12-19 2010-06-24 Shimoda Biotech (Pty) Ltd Inclusion complexes of alpha-cyclodextrin and sildenafil salt
RU2444989C1 (ru) * 2010-09-27 2012-03-20 Государственное образовательное учреждение высшего профессионального образования Первый Московский государственный медицинский университет им. И.М. Сеченова Министерства здравоохранения и социального развития Российской Федерации (ГОУ ВПО Первый МГМУ им. И.М. Сеченова Минздравсоцразвития России) Способ диагностики васкулогенной эректильной дисфункции
WO2017168174A1 (en) 2016-04-02 2017-10-05 N4 Pharma Uk Limited New pharmaceutical forms of sildenafil
IT201600119871A1 (it) * 2016-11-25 2018-05-25 Sabatino Russo Uso dell’associazione di inibitori della fosfodiesterasi 5 con prostaglandina e1 per il trattamento della disfunzione erettile
US11977085B1 (en) 2023-09-05 2024-05-07 Elan Ehrlich Date rape drug detection device and method of using same

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4696821A (en) 1983-10-11 1987-09-29 Warner-Lambert Company Transdermal delivery system for administration of nitroglycerin
US5256652A (en) 1987-11-12 1993-10-26 Pharmedic Co. Topical compositions and methods for treatment of male impotence
ATE173603T1 (de) 1990-04-25 1998-12-15 Vivus Inc Behandlung von erektionversagen
US5242391A (en) * 1990-04-25 1993-09-07 Alza Corporation Urethral insert for treatment of erectile dysfunction
AU2300092A (en) 1991-07-03 1993-02-11 Nathan E. Scott Prostaglandin e2 treatment of impotence
US5962528A (en) 1991-07-03 1999-10-05 Scott; Nathan Earl Prostaglandin E2 /F2α combination for treating impotence
US5252602A (en) * 1991-10-11 1993-10-12 Rafeul Alam Effects of misoprostol on allergic responses
US5773457A (en) * 1995-02-15 1998-06-30 Cesar Roberto Dias Nahoum Compositions
BR9203277A (pt) * 1992-08-21 1994-03-01 Cesar Roberto Dias Nahoum Utilizaccao de drogas eretogenicas e respectivas metodologias de aplicacao
US5324746A (en) 1993-02-12 1994-06-28 Mckee Rex N Method of treating damaged mucosal and epithelial tissues with misoprostol
US6007836A (en) 1993-05-28 1999-12-28 Vericade, Inc. Transdermal vasodilator
FR2710649A1 (fr) 1993-09-30 1995-04-07 Germinal Sarl Film polymérique à base de prolamines, son procédé de préparation et ses applications .
KR100422191B1 (ko) 1994-08-05 2004-05-20 인파머 에스. 에이. 포스페티딜콜린과착물화된프로스타글란딘e1및/또는트록세루틴을함유하는발기불능국부치료용조성물
US5612359A (en) 1994-08-26 1997-03-18 Bristol-Myers Squibb Company Substituted biphenyl isoxazole sulfonamides
CN1126587A (zh) 1995-01-10 1996-07-17 王怀秀 经阴囊睾酮缓释系统
HUP9801324A3 (en) 1995-03-14 1999-03-29 Vivus Inc Menlo Park Method and kit for preventing erectile dysfunction
US5731339A (en) 1995-04-28 1998-03-24 Zonagen, Inc. Methods and formulations for modulating the human sexual response
AUPN814496A0 (en) 1996-02-19 1996-03-14 Monash University Dermal penetration enhancer
US5688499A (en) 1996-03-13 1997-11-18 Queen's University At Kingston Antagonism of endothelin actions
US5684177A (en) 1996-05-17 1997-11-04 Torcan Chemical Ltd. Misoprostol
GR1002847B (el) 1997-05-06 1998-01-27 Χρηση της μισοπροστολης ή/και της μισοπροστολης οξυ για την παρασκευη φαρμακευτικου προιοντος για τη θεραπευτικη αντιμετωπιση των δυσλειτουργιων της στυσεως
US5976566A (en) 1997-08-29 1999-11-02 Macrochem Corporation Non-steroidal antiinflammtory drug formulations for topical application to the skin
AU740758B2 (en) 1997-10-28 2001-11-15 Vivus, Inc. Treatment of female sexual dysfunction
US6046244A (en) 1997-11-05 2000-04-04 Nexmed Holdings, Inc. Topical compositions for prostaglandin E1 delivery
US6277884B1 (en) 1998-06-01 2001-08-21 Nitromed, Inc. Treatment of sexual dysfunction with N-hydroxyguanidine compounds
US5942545A (en) 1998-06-15 1999-08-24 Macrochem Corporation Composition and method for treating penile erectile dysfunction
CA2353613A1 (en) 1998-12-02 2000-06-08 Shigeharu Suzuki Preparations for intraurethral administration
IL139941A0 (en) 1999-12-02 2002-02-10 Pfizer Prod Inc Use of prostaglandin agonists to treat erectile dysfunction or impotence
US6323241B1 (en) 2000-01-10 2001-11-27 Nexmed (Holdings) Inc. Prostaglandin compositions and methods of treatment for male erectile dysfunction
US6472398B1 (en) 2000-03-23 2002-10-29 Merck & Co., Inc. Spiropiperidine derivatives as melanocortin receptor agonists
US6476037B1 (en) 2000-03-23 2002-11-05 The Regents Of The University Of California L-arginine and phosphodiesterase (PDE) inhibitor synergism
AU2001249296B2 (en) 2000-03-23 2005-03-24 Merck Sharp & Dohme Corp. Substituted piperidines as melanocortin receptor agonists
WO2002009717A1 (fr) 2000-07-31 2002-02-07 Ono Pharmaceutical Co., Ltd. Remedes contre la dyserection contenant des derives de prostaglandine comme principe actif

Also Published As

Publication number Publication date
DE69822295T2 (de) 2005-02-24
US6210343B1 (en) 2001-04-03
JP2001525803A (ja) 2001-12-11
AU6848098A (en) 1998-11-27
DE980245T1 (de) 2000-08-31
PT980245E (pt) 2004-06-30
GR1002847B (el) 1998-01-27
EP0980245A1 (de) 2000-02-23
ES2216279T3 (es) 2004-10-16
WO1998050039A1 (en) 1998-11-12
DE69822295D1 (de) 2004-04-15
US6589990B1 (en) 2003-07-08
EP0980245B1 (de) 2004-03-10

Similar Documents

Publication Publication Date Title
ATE261307T1 (de) Verwendung von misoprostol und/oder misoprostolsäure zur behandlung von erektionsstörungen
DE69617469D1 (de) Behandlung von multipler sklerose
ES2191068T3 (es) Tratamiento profilactico y terapeutico de la sensibilizacion e irritacion de la piel.
DE69428523D1 (de) Verfahren zur behandlung von gemüts- oder geisteskrankheiten und von gemüts- oder geisteskrankheiten, die von anfällen begleitet sind
ES2052733T3 (es) Dispositivo electroterapeutico de baja frecuencia.
DE69731467D1 (de) Verfahren zur erhaltung von bestehenden körperfettgehalt und/oder körpergewicht
EA199700213A1 (ru) Крем на водной основе для локального применения, способ его приготовления, способ лечения эректильной дисфункции у мужчин, способ лечения аноргазма у женщин, способ лечения микроваскулярных заболеваний и способ лечения ран или хирургических рассечений
ATE233091T1 (de) Verwendung von histamine-2 agonisten zur behandlung sexueller funktionsstörungen
DE69613840D1 (de) Orale dosierungsform und verfahren zur behandlung von schmerzzuständen in dermundhöhle
DE69227306D1 (de) Behandlung von zellgewebsentzündung mit retinoide
DE69528602T2 (de) Prophylaktische behandlung der allergischen kontaktdermatitis
PT1173201E (pt) Metodo para o tratamento de fibrose utilizando um antagonista da subunidade alfa 4 de integrina
ATE453402T1 (de) Verwendung von serp-1 in kombination mit einem immunosuppressor zur behandlung von arthritis
DE69305267T2 (de) Zusammensetzung zur Behandlung von Mastitis und Metritis
ATE297739T1 (de) Endothelin-antagonisten zur behandlung von herzversagen
PT1007093E (pt) Metodos para o tratamento de desordens atraves da utilizacao de interleucina-9 e seus antagonistas
Finalay et al. Short contact crude coal tar therapy for psoriasis
ATE216884T1 (de) Verwendung von sulbutiamin zur behandlung von psychomotorischen oder psychointellektuellen beschwerden
DE69635282D1 (de) Behandlung der exzessiven aggressivität mit olanzapine
DE69430807D1 (de) Verfahren zur behandlung von lebererkrankungen und ähnlichen indikationen mit vasodilatierenden wirkstoffen
ATE302605T1 (de) Tazaroten und uvb-phototherapie zur behandlung von psoriasis
RU94020373A (ru) Способ лечения больных ревматоидным артритом
EA199700034A2 (ru) Способ в.г.соломатова коррекции энергетического состояния живого существа
李怀林 34 CASES OF HERPES ZOSTER TREATED BY MOXIBUSTION AT DAZHUI (Du 14)
DE69927985D1 (de) Verwendung von misoprostol oder/und misoprostol saüre zur herstellung eines arzneimittels zur behandlung weiblicher sexualer störung

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0980245

Country of ref document: EP

REN Ceased due to non-payment of the annual fee